From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-likegrowthfactor/insulin-likegrowthfactor-1receptor (IGF/IGF-1R) functional axis.
Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-likegrowthfactor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-likegrowthfactor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia .
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-likegrowthfactor-1 (IGF-1) levels in acromegaly patients.
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-likegrowthfactor-1 (IGF-1) levels in acromegaly patients.
Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Anamorelin (RC-1291) Fumarate is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin Fumarate can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-likegrowthfactor-1. Anamorelin Fumarate can be used in the research of anorexia and cancer cachexia .
Voglibose (Standard) is the analytical standard of Voglibose. This product is intended for research and analytical applications. Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-likegrowthfactor/insulin-likegrowthfactor-1receptor (IGF/IGF-1R) functional axis[1].
IGF-1R inhibitor-2 (example 121) is an insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis .
Picropodophyllin-d3 (AXL1717-d3; Picropodophyllotoxin-d3; PPP-d3) is the deuterium labeled Picropodophyllin (HY-15494). Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Anamorelin (Standard) (RC-1291 (Standard)) is the analytical standard of Anamorelin (HY-14734). This product is intended for research and analytical applications. Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-likegrowthfactor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-likegrowthfactor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-likegrowthfactor-1receptor (IGF-1R) and insulinreceptor (IR), with IC50s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC50>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-likegrowthfactor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-likegrowthfactor-1receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50?of 1 μM .
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-likegrowthfactor 1receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-likegrowthfactor 1receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 has antitumor activity .
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-likegrowthfactor 1receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity .
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-likegrowthfactor 1receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-likegrowthfactor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research .
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-likegrowthfactor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research .
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-likegrowthfactor 1receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-likegrowthfactor 1receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-likegrowthfactor/insulin-likegrowthfactor-1receptor (IGF/IGF-1R) functional axis.
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Voglibose (Standard) is the analytical standard of Voglibose. This product is intended for research and analytical applications. Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-likegrowthfactor/insulin-likegrowthfactor-1receptor (IGF/IGF-1R) functional axis[1].
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-6*His labeled tag.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His, solution) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (His) is the recombinant human-derived IGF-I R protein, expressed by E. coli , with N-6*His labeled tag.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (sf9, His-GST) is the recombinant human-derived IGF-I R protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, Fc) is the recombinant human-derived IGF-I R protein, expressed by HEK293, with C-hFc labeled tag.
Picropodophyllin-d6 (AXL1717-d6) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
Picropodophyllin-d3 (AXL1717-d3; Picropodophyllotoxin-d3; PPP-d3) is the deuterium labeled Picropodophyllin (HY-15494). Picropodophyllin (AXL1717) is a selective insulin-likegrowthfactor-1receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221
WB, IHC-P
Human
IGF1 Receptor Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to IGF1 Receptor. It can be used for WB,IHC-P assays with tag free, in the background of Human.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221
WB, IP
Human, Mouse, Rat
Phospho-IGF1 Receptor (Tyr1166) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 155 kDa, targeting to Phospho-IGF1 Receptor (Tyr1166). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221
WB, IHC-P, ICC/IF, ELISA
Human
IGF-1R Antibody (YA4905) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IGF-1R. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221
WB, IHC-P, ICC/IF, ELISA
Human
IGF-1R Antibody (YA4906) is a mouse-derived and non-conjugated monoclonal antibody, targeting to IGF-1R. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221
WB, IHC-P, ICC/IF, IP, ELISA
Human
IGF-1R Antibody (YA6321) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IGF-1R. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.
IGF1R; Insulin-likegrowthfactor 1 receptor; Insulin-likegrowthfactor I receptor; IGF-I receptor; CD antigen CD221; INSR; Insulinreceptor; IR; CD antigen CD220
WB, ICC/IF, IP, ELISA
Human, Mouse, Rat
Phospho-IGF1R(Tyr1135/1136)/Insulin Receptor β(Tyr1150/1151) Antibody (YA5768) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to phosphorylated IGF1R (Tyr1135/1136)/Insulin Receptor β (Tyr1150/1151). It can be applicated for WB, ICC/IF, IP, ELISA assays, in the background of human, mouse, rat.
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-likegrowthfactor-1 (IGF-1) levels in acromegaly patients.
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-likegrowthfactor-1 (IGF-1) levels in acromegaly patients.
Inquiry Online
Your information is safe with us. * Required Fields.
